Antibodies to kallidin and des-Arg9-kallidin

US9376494B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Han Li · Xi'an, CN
• Dorothea Kominos · Millington, US
• Jie Zhang · Beijing, CN
• Alla Pritsker · Cambridge, US
• Matthew Davison · Oklahoma City, US
• Nicolas Baurin · Arpajon, FR
• Govindan Subramanian · Fort Lee, US
• Xin Chen · Lexington, US

Key dates

• Filing date: Mar 15, 2013
• Grant date: Jun 28, 2016
• Expiry date: Mar 15, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N15/63
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.